PROCESSO PARA A PREPARAÇÃO DE UM COMPOSTO DE AMINA, COMPOSTO DE 2,5-DIMETILINDANO, COMPOSTO E PROCESSOS PARA A PREPARAÇÃO DE INDAZIFLAM
The described process enhances the synthesis of Indaziflam intermediates by using a transition metal complex with a chiral ligand for amination, addressing non-enantioselectivity and low yield issues in existing methods, achieving improved efficiency and selectivity.
Patent Information
- Application Number
- BR112025020913
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-29
- Filing Date
- 2024-03-28
- Publication Date
- 2026-11-10
AI Technical Summary
Existing methods for synthesizing Indaziflam intermediates face challenges with non-enantioselective synthesis and low yield, requiring complex separation of isomers and enantiomers.
A process involving the amination of indene compounds with a hydrosilane reducing agent and a catalyst comprising a transition metal complex with a chiral ligand, such as copper(II) acetate and a bidentate phosphorus ligand, to achieve high enantioselectivity and yield.
The process enables the production of Indaziflam intermediates with improved enantioselectivity and yield, simplifying the synthesis and overcoming the limitations of prior art methods.
Abstract
Description
1 / 46 PROCESS FOR THE PREPARATION OF AN AMINE COMPOUND, 2,5-DIMETHYLINDANE COMPOUND, AND PROCESSES FOR THE PREPARATION OF INDAZIFLAM. TECHNICAL AREA
[0001] This disclosure relates to the field of agrochemicals. More specifically, it concerns a process for preparing amines as intermediates for the synthesis of triazines, which are suitable as herbicides for controlling weeds. BACKGROUND
[0002] Triazine compounds are a class of compounds suitable for use as herbicides. Triazine compounds such as Atrazine, Ametryn, Indaziflam, or Triaziflam are among the compounds that are used as herbicides.
[0003] The synthesis of Indaziflam was first disclosed in document WO04 / 069814 Al. A compound of Formula (V) is mentioned as a starting material in one of the alternative syntheses described in the aforementioned prior art document. R9 Formula (V) where: R6 is alkyl (C1-C1); Petition 870260107969, dated 10 / 21 / 2026, pp. 37 / 38 2 / 46 A is CH2, 0, or a direct link, according to document WO 04 / 069814 Al.
[0004] Compounds of Formula (V) have been described as being prepared according to known methods, for example, by reductive amination of ketones or the corresponding oximes. However, this synthesis requires the separation of mixtures of 4 isomers, that is, cis / trans isomers and enantiomers, as disclosed in the examples of this document.
[0005] The synthesis of a compound with formula (IA, 2S)-2,6-dimethyl-2,3-dihydro-1-indan-1-amine was also described in document WO 2015 / 113903 Al: (IR,2S)-2,6-dimethyl-2,3-dihydro-1-indan-1-amine was prepared from 2-[1-(2-bromo-5-methylphenyl)-2methylpropyl]-IH-isoindol-1,3(2H)-dione by means of 2[(1R,2S)-2,6-dimethyl-2,3-dihydro-1H-inden-1-yl]-1Hisoindol-1,3(2H)-dione using a palladium tetraphenylphosphine catalyst with 55% yield of the halogenated compound.
[0006] An additional approach described in document CN 108794339, which refers to the separation of (1A,2S)-2,6-dimethyl-1-aminoindane (I) from the mixture (III) of four isomers as feedstock. Initially, a mixture of enantiomers of compounds of Formula (II), enriched in trans isomers, is prepared by means of a method of Petition 870250088165, dated 09 / 29 / 2025, p. 21 / 82 3 / 46 hydrogenation in the presence of a palladium catalyst, or a salifying crystallization method with achiral organic acid, or both methods; using R-mandelic acid to separate a mixture of enantiomers of Formula (II) to obtain (IR, 2S)-2,6-dimethyl-1-aminoindane enriched with the RS-(I) enantiomer. The residual isomer generated in the preparation method can be converted into the compound shown as Formula (II) and enriched with the trans isomer through a catalytic palladium hydrogenation method for recycling. (III)
[0007] Bayer's process for the synthesis of Indaziflam is described in document US 2004 / 157739. According to this process, in Step 1, a homogeneous mixture of (IR,2S)-1-amino-2-methylindane hydrochloride and 1-cyanoguanidine in 1,3-dichlorobenzene was heated to 140-150 °C. The cooled mixture was diluted with toluene and the solid filtered to give solid (IR,2S)-1-(bisguanidino)-2-methylindane monohydrochloride.
[0008] In Step 2, a 30% solution of sodium methoxide in methanol was added to a stirred suspension of (IR, 2S)-1-(bisguanidino)-2-methylindane monohydrochloride in methanol. Then, methyl-(2R)-2-fluoropropanoate was added at room temperature, followed by an additional amount of 30% sodium methoxide solution. The residue was purified by column chromatography, eluting Petition 870250088165, dated 09 / 29 / 2025, page 22 / 82 4 / 46 with a mixture of ethyl acetate:heptane (7:3) as eluent to give 2-amino-4-[(IF,2S)-2-methyl-lindanylamino]-6-[(IA)-1-fluoroethyl]-1,3,5-triazine (Indazifiam). ci nh3+ l-cyanoguanidine N=—NH Step 1 ^)=NH -----► HnN
[0009] Therefore, due to the complex synthesis of the intermediate Indazifiam, (1R,2S)-2,6-dimethyl-2,3-dihydro-1H-inden-lamine, there is a need in the art for a simple reaction to operate, with high enantioselectivity and / or yield, and from a simple and readily available starting material. SUMMARY
[0010] Some embodiments of the present disclosure provide an alternative to existing methods for the preparation of Indaziflam intermediates. It is also an objective of the present disclosure to provide a process that solves at least some of the disadvantages of prior art methods, such as non-enantioselective synthesis and / or low yield.
[0011] Some embodiments refer to a process for the preparation of an amine compound of Formula (I): in which: Petition 870250088165, dated 09 / 29 / 2025, p. 23 / 82 5 / 46 R1 and R2 could each independently be hydrogen or an optionally substituted C1-C4 alkyl group, wherein R1 and R2 are not both hydrogen; R3 and R4 could each independently be hydrogen, an optionally substituted C1-C3 alkyl group, an optionally substituted C1-C3 alkenyl group, an optionally substituted aryl group, a phenyl group, or an aralkyl group with a C1-C4 alkyl chain; wherein the optional substituent may be selected from the group comprising halogen, aliphatic, halo aliphatic, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; A could be -CH2-, -O-, or a direct link; en could be 0, 1, 2, or 3; which could comprise the amination of an indene compound of Formula (II) Formula (II) with an amination agent selected from a compound of Formula (IV) or Formula (VI), R5 R9 R10 Formula (IV) Formula (VI) where: R5 is COOR6, OR7 or OC=OR8; R6, R7 and R8 are each independently hydrogen, an optionally substituted C1-C4 alkyl chain or Petition 870250088165, dated 09 / 29 / 2025, page 24 / 82 6 / 46 an optionally substituted aryl group, wherein the optional substituent is selected from among one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; R9 and R10 are each independently an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; A' could be -CH2- or a direct link; and A'' could be a fused benzene ring optionally replaced by (R2)n, where ne R2 could be as defined in Formula (I); where amination could occur in the presence of a hydrosilane reducing agent and a catalyst, where the catalyst could be a complex of a transition metal with a chiral monodentate, bidentate, or polydentate ligand.
[0012] According to some embodiments, R1 and R2 could each independently be a C1-C4 alkyl group and could be 1. According to some embodiments, R3 and R4 could each independently be hydrogen.
[0013] According to some embodiments, the amination may be carried out in a solvent. According to some embodiments, the solvent could be selected from a group that includes tetrahydrofuran, 2-methyltetrahydrofuran, cyclohexane, methylcyclohexane, toluene, n-heptane, ether Petition 870250088165, dated 09 / 29 / 2025, p. 25 / 82 7 / 46 tert-butyl methyl, cyclopentyl methyl ether, chlorobenzene, diethyl ether, dichloromethane, 1,2dichloroethane, 1,4-dioxane, acetonitrile, dimethylacetamide, dimethoxymethane, 2-methyl tetrahydrofuran and xylene.
[0014] According to some embodiments, the solvent may be selected from a group that includes tetrahydrofuran, 2-methyltetrahydrofuran, cyclohexane, methylcyclohexane, toluene and n-heptane. Alternatively, according to some embodiments, the solvent may preferably be selected from a group that includes tetrahydrofuran, 1,2-dichloroethane, 1,4-dioxane, acetonitrile, dimethylacetamide, dichloromethane, cyclopentyl methyl ether and dimethoxymethane.
[0015] According to some embodiments, the hydrosilane reducing agent could be selected from the group that includes alkoxy-hydrosilanes or hydrosiloxanes. According to some embodiments, the hydrosilane reducing agent could be selected from the group that includes methyldimethoxysilane, trimethoxysilane or poly(methyl-hydrosiloxane).
[0016] According to some embodiments, the transition metal could be a cationic transition metal. According to some embodiments, the transition metal could have an oxidation state of 0, +1, +2, +3, or +4. According to some embodiments, the transition metal could preferably have a transition state of +2. According to some embodiments, the transition metal could be selected from the group that includes Cu2+, Ni2+, Pd2+, Pt2+, Fe2+, Ru2+, Cr2+, Mo2+, W2+, Co2+, or Mn2+. According to some embodiments, the transition metal could preferably be Cu2+ or Ni2+. Petition 870250088165, dated 09 / 29 / 2025, p. 26 / 82 8 / 46
[0017] According to some embodiments, Cu2+ could be selected from the group that includes copper(II) acetate, copper(II) nitrate, copper(II) carbonate, copper(II) sulfate, copper(II) trifluoroacetate, copper(II) triflate, copper(II) bis(trifluoromethylsulfonyl)imide, copper(II) perchlorate, copper(II) tetrafluoroborate hexahydrate.
[0018] According to some embodiments, Ni2+ could be selected from the group that includes nickel diiodide, nickel(II) tetrafluoroborate hexahydrate, nickel(II) bis(acetylacetonate), nickel dichloride, nickel difluoride tetrahydrate and nickel(II) trifluoroacetate.
[0019] According to some embodiments, the catalyst is a complex of a transition metal with a chiral ligand, and can be prepared in situ or ex situ.
[0020] According to some embodiments, the chiral ligand may be a monodentate, bidentate, or polydentate chiral ligand. According to some embodiments, the chiral ligand may be a bidentate chiral ligand. According to some embodiments, the chiral ligand may be a bidentate chiral ligand containing phosphorus. According to some embodiments, the chiral ligand may be a bidentate chiral ligand containing nitrogen.
[0021] According to some embodiments, the bidentate chiral ligand containing phosphorus selected from the group that includes (+)-1,2-bis((2S,5S)-2,5-diphenylphospholane)ethane, (+)-1,2bis((2S,5S)-2,5-dipropylphospholane)ethane, (-)-1,2bis[(2R,5R)-2,5-diethylphospholane]benzene, (-)-1,2bis[(2R,5R)-2,5-dimethylphospholane]benzene, 1,2-bis(diphenylPetition 870250088165, dated 09 / 29 / 2025, page 27 / 82 9 / 46 phosphino)ethane (DPPE), (+)-2,2-dimethyl-4,5-((diphenylphosphino)dimethyl)dioxolane, (2S,4S)-(-)-4-diphenylphosphino-2(diphenylphosphinomethyl)pyrrolidine, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl) (BINAP) and (-)-1,2-bis[(2R,5R)-2,5-dimethylphospholane]benzene, derivatives and enantiomers thereof. According to some embodiments, the chiral bidentate ligand containing phosphorus may be (+)-1,2-bis((2S,5S)2,5-diphenylphospholane)ethane.
[0022] According to some embodiments, the nitrogen-containing bidentate chiral ligand could be selected from the group that includes: (3aR,3'aR,8aS,8'aS)-3a,3'a,8a,8'a-tetrahydro-8H,8'H-2,2'-biindeno[1,2-d]oxazole, (5R,5'R)-5,5'-diisobutyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)5,5'-diphenyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)5,5'-dibenzyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-di-tert-butyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-dimethyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-diisopropyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, derivatives and enantiomers thereof. According to some embodiments, the nitrogen-containing bidentate chiral ligand could preferably be selected from the group that includes: (3aR,3'aR,8aS,8'aS)-3a,3'a,8a,8'atetrahydro-8H,8'H-2,2'-biindeno[1,2-d]oxazole, (5R,5'R)5,5'-di-tert-butyl-4,4',5,5'-tetrahydro-2,2'-bioxazole and (5R,5'R)-5,5'-diphenyl-4,4',5,5'-tetrahydro-2,2'-bioxazole. According to some embodiments, the nitrogen-containing bidentate chiral ligand could preferably be (3aR,3'aR,8aS,8'aS)-3a,3'a,8a,8'a-tetrahydro-8H,8'H-2,2'-biindene[1,2-d]oxazole or (5R,5'R)-5,5'-di-tert-butyl4,4',5,5'-tetrahydro-2,2'-bioxazole. Petition 870250088165, dated 09 / 29 / 2025, p. 28 / 82 10 / 46
[0023] According to some embodiments, the aminating agent could be a compound of Formula (IV), wherein: R5 is COOR6, OR7 or OC=OR8; R6, R7 and R8 are each independently hydrogen, an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; R9 and R10 are each independently an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; Preferably, a compound of formula (I) in which A' could be -CH2-; A'' could be a fused benzene ring optionally replaced by (R2)n, where ne R2 could be as defined in Formula (I); en could be 0.
[0024] According to some embodiments, the aminating agent could be selected from the group that includes 1,2-benzisoxazole, (Bn)2NOBz (O-benzoyl-N,N-dibenzylhydroxylamine), (Bn)2NOAc (O-acetyl-N,N-dibenzyl Petition 870250088165, dated 09 / 29 / 2025, p. 29 / 82 11 / 46 hydroxylamine) and (Bn)2NCO2Et. According to some embodiments, the amination agent could preferably be 1,2-benzisoxazole (Bn)2NOBz or (Bn)2NOAc.
[0025] According to some embodiments, the amination could occur at a temperature in the range between about 0-100 °C.
[0026] According to some embodiments, amination could occur at a temperature in the range of about 0-40°C when the transition metal is Ni.
[0027] According to some embodiments, amination could occur at a temperature in the range of about 0-40°C when the transition metal is Ni
[0028] According to some embodiments, amination could occur at a temperature in the range of about 30-80 °C when the transition metal is Cu.
[0029] According to some embodiments, amination could occur at a temperature in the range of about 30-80 °C when the transition metal is Cu
[0030] According to some methods, amination may occur under atmospheric pressure.
[0031] According to some embodiments, the process may include the addition of a hydrolyzing agent to hydrolyze an initially formed imine derivative to obtain a free amine or a salt thereof. According to some embodiments, the hydrolyzing agent may be selected from among: NH2OH-HCl, NH3 (ammonia), N2H4 (hydrazine), and NH2OH 50% by weight in H2O.
[0032] According to some embodiments, the aminating agent may be a compound of Formula (IV), wherein: R5 is COOR6, OR7 or OC=OR8; Petition 870250088165, dated 09 / 29 / 2025, page 30 / 82 12 / 46 R6, R7 and R8 are each independently hydrogen, an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; R9 and R10 are each independently an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro.
[0033] According to some embodiments, the process may include the addition of an additive selected from the group that includes sodium iodide (NaI), potassium iodide (KI), lithium iodide (LI) and cesium iodide (CSI).
[0034] According to some embodiments, the compound of Formula (I) could be (IR, 2S)-1-amino-2,6-dimethylindane (Formula VII) or (IR,2S)-1-dibenzylamino-2,6-dimethylindane.
[0035] According to some embodiments, (IR, 2S)-1-amino-2,6-dimethylindane (Formula (VII)) Formula (VII) could be produced by the reaction of 2,5-dimethylindene having a Formula (VIII) Petition 870250088165, dated 09 / 29 / 2025, p. 31 / 82 13 / 46 Formula (VIII) with 1,2-benzisoxazole in the presence of copper(II) acetate (Cu(OAc)2), (+)-1,2-bis(2,3,5S)-2,5-diphenylphospholane)ethane ((S,S)-Ph-BPE) and poly(methylhydrosiloxane) (PMHS).
[0036] According to some embodiments, the process for producing (1R,23)-1-amino-2,6-dimethylindane (Formula (VII)) could further include the addition of NH2OH-HC1.
[0037] According to some models, the process could occur under a nitrogen atmosphere.
[0038] Some embodiments refer to a process for the preparation of an indene compound of Formula (II): ...R1 Formula (II) by dehydration of an indanol compound of Formula (III): OH / L / R1,RXXJ Formula (III) where: R1 and R2 may each independently be hydrogen, and wherein R1 and R2 are not both hydrogen or an optionally substituted C1-C4 alkyl group, wherein the optional substituents may be selected from the group that includes halogen, aliphatic, halo aliphatic, alicyclic, alkoxy, thioalkyl, cyano or nitro groups;
[0039] A could be -CH2-, -O- or a direct link; and Petition 870250088165, dated 09 / 29 / 2025, p. 32 / 82 14 / 46 n could be 0, 1, 2, or 3.
[0040] According to some embodiments, dehydration may be carried out in a solvent. According to some embodiments, the dehydration solvent may be selected from the group that includes toluene, chlorobenzene, dichloroethane, and xylene. According to some embodiments, the dehydration solvent may preferably be toluene.
[0041] According to some embodiments, dehydration may be carried out in the presence of a catalyst. According to some embodiments, the catalyst may be selected from the group that includes p-toluenesulfonic acid, pyridinium p-toluenesulfonic acid, sulfosalicylic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, p-bromosulfonic acid, sulfuric acid, trifluoromethanesulfonic acid and hydrochloric acid.
[0042] Some embodiments refer to a 2,5-dimethylindene compound of Formula (VIII) Formula (VIII).
[0043] Some modalities refer to a compound of in which: Petition 870250088165, dated 09 / 29 / 2025, p. 33 / 82 15 / 46 R1 and R2 may each independently be hydrogen, and wherein R1 and R2 are not both hydrogen or an optionally substituted C1-C4 alkyl group, and wherein R1 and R2 may not both be hydrogen; R12 may be hydrogen, an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent may be selected from one or more substituents in the group including halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; and The A could be -CH2-, -O-, or a direct bond.
[0044] Some modalities refer to a compound of Formula (IX): Formula (IX).
[0045] According to some forms, a compound of Formula (IX) or Formula (X) could be an intermediate in the preparation of a compound of Formula (I).
[0046] Some embodiments refer to a process for the preparation of Indaziflam, the process comprising the preparation of a compound of Formula (I) according to a process as disclosed in this document.
[0047] Some embodiments refer to Indaziflam produced in accordance with a process as disclosed in this document. Petition 870250088165, dated 09 / 29 / 2025, p. 34 / 82 16 / 46
[0048] The compound of Formula (I) is an important intermediate and is used in the preparation of Indaziflam, as described in documents WO 2009 / 077059 and US 2004 / 0157739, which are incorporated herein by reference in their entirety.
[0049] According to some embodiments, an additional aspect of the object is provided: a process for the preparation of Indaziflam, including: a) prepare the compound of Formula (I) as described in this document; b) to provide reaction conditions for the preparation of Indaziflam.
[0050] According to one embodiment, the reaction conditions in step (b) include, among others, nucleophilic addition reaction and cyclization to obtain Indaziflam.
[0051] Some embodiments refer to a process for the preparation of Indaziflam, the process including: a. react (1R,2S)-1-amino-2,6-dimethylindane prepared according to any of the disclosed embodiments with 1-cyanoguanidine in the presence of a solvent to obtain (1R,2S)-1-(bisguanidino)-2,6-dimethylindane; and b. react the aforementioned (1R,2S)-1-(bisguanidino)-2,6-dimethylindane with methyl-(2R)-2-fluoropropanoate in the presence of a base and in the presence of a solvent.
[0052] Some embodiments refer to a process for the preparation of Indaziflam, the process including: a. react (1R,2S)-1-amino-2,6-dimethylindane prepared according to any of the disclosed embodiments with 1-cyanoguanidine and metal isopropoxide in the presence of a solvent to obtain (1R,2S)-1(bisguanidino)-2,6-dimethylindane; and Petition 870250088165, dated 09 / 29 / 2025, p. 35 / 82 17 / 46 b. react the aforementioned (1R,2S)-1-(bisguanidino)-2,6-dimethylindane with methyl-(2R)-2-fluoropropanoate.
[0053] Some embodiments refer to a process for the preparation of Indaziflam, the process including: a. react (1R,2S)-1-amino-2,6-dimethylindane prepared according to any of the disclosed embodiments with cyanoguanidine and aluminum isopropoxide in the presence of a solvent to obtain (1R,2S)-1(bisguanidino)-2,6-dimethylindane; and b. react the aforementioned (1R,2S)-1-(bisguanidino)-2,6-dimethylindane with methyl-(2R)-2-fluoropropanoate.
[0054] Additional features and advantages of the present disclosure will become apparent to those skilled in the art by considering the following detailed description of illustrative embodiments that exemplify the best way to realize the utility described in this document, as currently perceived. DETAILED DESCRIPTION
[0055] According to some embodiments, an alternative to existing methods for the preparation of Indaziflam intermediates is provided. Advantageously, in some embodiments, a chiral synthesis can be used to prepare Indaziflam intermediates. Advantageously, by careful selection of a chiral ligand, the enantiomeric excess and / or yield can be controlled. Definitions
[0056] The modalities of this disclosure are discussed in detail below. In describing the modalities, specific terminology is employed for the sake of clarity. However, the disclosure is not intended to be limited to Petition 870250088165, dated 09 / 29 / 2025, p. 36 / 82 18 / 46 specific terminology thus selected. Although specific exemplary embodiments are discussed, it should be understood that this is done for illustrative purposes only. A person skilled in the relevant art will recognize that other components and configurations may be used without departing from the spirit and scope of the disclosure. Although a number of embodiments and features are described in this document, it should be understood that the various features of the disclosure and aspects of the embodiments, even if described separately, may be combined unless mutually exclusive or contrary to the specific description. All references cited herein are incorporated by reference as if each had been incorporated individually.
[0057] As used in this document, the transitive term comprising or “that which includes,” which is synonymous with “including or containing,” is inclusive or open-ended and does not exclude additional, unrecorded elements or steps of the method. However, in each recitation of “comprising,” the term is intended to also encompass, as alternative modalities, the phrases “essentially consisting of” and “consisting of,” where “consisting of” excludes any unspecified element or step and “essentially consisting of” allows the inclusion of additional unrecorded elements or steps that do not materially affect the essential or basic and innovative characteristics of the composition or method under consideration.
[0058] Furthermore, unless expressly stated otherwise, either refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by Petition 870250088165, dated 09 / 29 / 2025, page 37 / 82 19 / 46 any of the following conditions: A is true (or present) and B is false (or absent), A is false (or absent) and B is true (or present), and both A and B are true (or present).
[0059] Before detailing the present subject matter, definitions are provided for certain terms to be used in this document. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as that commonly understood by a person skilled in the art to which the present subject matter pertains.
[0060] The term "a" or "an," as used in this document in accordance with certain modalities, may include both the singular and the plural, unless specifically indicated otherwise. Therefore, the terms "a," "an," or "at least one" may be used interchangeably in this application.
[0061] As used in this document, the term compound may include all its forms, including, but not limited to, salts, solid forms, such as amorphous, crystalline, solvate or hydrate.
[0062] As used in this document, the term aryl group, as used in this document according to some embodiments, may refer to an optionally substituted aromatic carbocyclic or heterocyclic group, which has between 4 and 10, between 5 and 10, between 5 and 8 carbon atoms, comprising 1 aromatic ring or 2 fused aromatic rings, wherein the optional substituents are selected from the group that includes halogen, aliphatic, haloaliphatic, alkoxy, thioalkyl, cyano or nitro groups. In the case of a heterocyclic aryl group, i.e., a heteroaryl group, 1, 2 or 3 of the atoms in the ring or rings of the aryl group are elements Petition 870250088165, dated 09 / 29 / 2025, p. 38 / 82 20 / 46 different from carbon, such as nitrogen, oxygen or sulfur.
[0063] The term aralkyl group, as used in this document in some embodiments, may refer to an alkyl group substituted by aryl.
[0064] The term alkoxy group, as used in this document in accordance with some embodiments, may refer to an alkyl group bonded to oxygen.
[0065] The term aryloxy group, as used in this document in accordance with some embodiments, may refer to an aryl group attached to oxygen.
[0066] The term aralkoxy group, as used in this document in accordance with some embodiments, may refer to an aralkyl group bonded to oxygen.
[0067] The term aralkoxiamine group, as used in this document in accordance with some embodiments, may refer to an aralkyl group attached to oxygen which, in turn, is linked to nitrogen by a single bond.
[0068] The term alkoxyamine, as used in this document in accordance with some embodiments, may refer to an alkyl group attached to oxygen which, in turn, is attached to nitrogen by a single bond.
[0069] The term isoxazole, as used in this document in accordance with some embodiments, may refer to an aromatic heterocycle containing an NO linkage.
[0070] The term benzisoxazole, as used in this document in accordance with some embodiments, may refer to a bicyclic heterocycle including a benzene ring fused to an aromatic heterocycle containing an NO linkage. Petition 870250088165, dated 09 / 29 / 2025, p. 39 / 82 21 / 46
[0071] The term thioalkyl group, as used in this document in some embodiments, may refer to an alkyl group bonded to sulfur. The term haloaliphatic group, as used in this document in some embodiments, may refer to an aliphatic group substituted with at least one halogen atom.
[0072] The term aliphatic group, as used in this document in accordance with some embodiments, may include, for example, and not be limited to, linear or branched alkyl, alkenyl and alkynyl groups.
[0073] The term alkyl group, as used in this document in some embodiments, may refer to a saturated, linear or branched group which has between 1 and 24, between 1 and 16, between 1 and 14, between 1 and 12, or 1, 2, 3, 4, 5 or 6 carbon atoms and is linked to the rest of the molecule by a single bond, including, for example and not limited to, methyl, ethyl, isopropyl, isobutyl, tert-butyl, heptyl, octyl, decyl, dodecyl, hexadecyl, octadecyl, amyl, 2-ethylhexyl, 2-methylbutyl, 5-methylhexyl and the like.
[0074] The term alkenyl group, as used in this document in some embodiments, may refer to a linear or branched group, which has between 2 and 24, between 2 and 16, between 2 and 14, between 2 and 12, or 2, 3, 4, 5 or 6 carbon atoms, with 1, 2 or 3 carbon-carbon double bonds, conjugated or non-conjugated, which is linked to the rest of the molecule by a single bond, including, for example, but not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, pentenyl and similar groups. Petition 870250088165, dated 09 / 29 / 2025, p. 40 / 82 22 / 46
[0075] The term alkynyl group, as used in this document in some embodiment, may refer to a linear or branched group, which has between 2 and 24, between 2 and 16, between 2 and 14, between 2 and 12, or 2, 3, 4, 5 or 6 carbon atoms, with 1, 2 or 3 carbon-carbon triple bonds, conjugated or non-conjugated, which is linked to the rest of the molecule by a single bond, including, for example, but not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, penthynyl, such as 1-pentynyl, and the like.
[0076] The term “alkylidene group,” as used in this document and in some embodiments, may refer to a saturated, linear or branched group which has between 1 and 24, between 1 and 16, between 1 and 14, between 1 and 12, or 1, 2, 3, 4, 5 or 6 carbon atoms and is linked to the rest of the molecule by a double bond, including, for example, but not limited to, methylidene, ethylidene, isopropylidene, isobutylidene, tert-butylidene, heptylidene, octylidene, decylidene, dodecylidene, hexadecylidene and the like.
[0077] The term “alicyclic group”, as used in some embodiments, could include, for example, but not be limited to, cycloalkyl, cycloalkenyl and / or cycloalkynyl groups.
[0078] The term cycloalkyl, as used in this document in some embodiments, may refer to a saturated mono- or polycyclic aliphatic group having between 3 and 24, between 3 and 16, between 3 and 14, between 3 and 12, or 3, 4, 5 or 6 carbon atoms and which is linked to the rest of the molecule by a single bond, including, for example, and Petition 870250088165, dated 09 / 29 / 2025, p. 41 / 82 23 / 46 not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, methylcyclohexyl, dimethylcyclohexyl, octahydroindene, decahydronaphthalene, dodecahydrophenole and / or similar substances.
[0079] The term cycloalkenyl, as used in this document in some embodiments, may refer to a non-aromatic mono- or polycyclic aliphatic group, which has between 5 and 24, between 5 and 16, between 5 and 14, between 5 and 12, or 5 or 6 carbon atoms, with 1, 2 or 3 carbon-carbon double bonds, conjugated or non-conjugated, and which is linked to the rest of the molecule by a single bond, including, for example, but not limited to, the cyclopent-1-en-1-yl group and / or similar groups.
[0080] The term cycloalkynyl, as used in this document in some embodiments, may refer to a non-aromatic mono- or polycyclic aliphatic group, which has between 8 and 24, between 8 and 16, between 8 and 14, between 8 and 12, or 8 or 9 carbon atoms, with 1, 2 or 3 carbon-carbon triple bonds, conjugated or non-conjugated, and which is linked to the rest of the molecule by a single bond, including, for example, but not limited to, cyclo-oct-2-in-1-yl groups and / or similar groups.
[0081] The term hydrosilane, as used in this document in some embodiment, may refer to any tetravalent silicon organic compound containing one or more Si-H bonds. The term alkoxyhydrosilane, as used in this document, refers to any tetravalent silicon organic compound containing one or more Si-H bonds and one or more alkoxy groups bonded to silicon. For example, and not limited to, methyldimethoxysilane, Petition 870250088165, dated 09 / 29 / 2025, p. 42 / 82 24 / 46 trimethoxysilane, dimethoxysilane, diethoxysilane, triethoxysilane, poly(methylhydrosilane), oligosilanes and / or the like.
[0082] The term hydrosiloxane, as used in this document in some embodiments, may refer to any organosilicon compound containing at least one Si-O-Si group, wherein each Si atom carries two aliphatic or aralkyl groups. The term alkoxyhydrosiloxanes, as used in this document, refers to any organosilicon compound containing at least one Si-O-Si group, wherein each Si atom carries two aliphatic or aralkyl groups, at least one of which is an alkoxy group. For example, and not limited to, polymethylhydrosiloxane (PMHS), phenylsiloxane, oligosiloxane, methyldimethoxysiloxane, trimethoxysiloxane, dimethoxysiloxane, dietoxysiloxane and / or the like.
[0083] The terms monodentate chiral ligand, bidentate chiral ligand, and polydentate chiral ligand, as used herein in accordance with some embodiments, may refer to a chiral ligand linked to the rest of the molecule by a single or double bond, and the rest of the molecule may be an organic or organometallic molecule, wherein the chiral ligand includes a single donor atom, two donor atoms, or multiple donor atoms.
[0084] Non-limiting examples of monodentate ligands are: [(1R)-2'-methoxy[1,1'-binaphthalen]-2-yl]diphenylphosphine, (1R)-[1,1'-binaphthalen]-2-yldiphenylphosphine, [(2S)-2-(1-naphthalenyl)[1,1'-biphenyl]-3-yl]diphenylphosphine, [(1S,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]diphenylphosphine, 3-(diphenylphosphino)-2-Petition 870250088165, dated 29 / 09 / 2025, p. 43 / 82 25 / 46 [(R)-methoxyphenylmethyl]-(3S)-ferrocene, derivatives or enantiomers thereof and / or similar.
[0085] The term bidentate chiral ligand containing phosphorus, as used in this document in some embodiments, may refer to a bidentate chiral ligand containing one or more phosphorus atoms, which is linked to the rest of the molecule by a single or double bond, and the rest of the molecule may be an organic or organometallic molecule. For example, and not limited to: ( + )-1,2-bis((2S ,5S) 2,5-diphenylphosphonate)ethane, dipropylphosphonate)ethane, diethylphosphone]benzene, dimethylphosphonate]benzene, dimethylphosphonate]benzene, dimethylphosphone]ethane, bis(diphenylphosphine)ferrocenyl bis(diphenylphosphine) bis(dicyclohexylphosphine)ethane bis(diphenylphosphine)propane bis(diphenylphosphine)butane (+)-1,2-bis((2S,5S)-2,5(-)-1,2-bis[(2R,5R)-2,5(-)-1,2-bis[(2R,5R)-2,5(-)-1,2-bis[(2R,5R)-2,5(-)-1,2-bis [(2S,5S)-2,51-(S)-1,2ethylamine,1,2(DPPE),1,2(DCPE),1,3(DPPP),1,4(DPPB),1,1'bis(diphenylphosphino)ferrocene (DPPF), (+)-2,2-dimethyl-4,5((diphenylphosphino)dimethyl)dioxolane, (2S,4S)-(-)-4diphenylphosphino-2-(diphenylphosphinemethyl)pyrrolidine,2(buciclo-hexane)-1-(diphenylphosphino)ferrocene,2,2'bis(diphenylphosphino)-1,1'-binaphthyl) (BINAP), (-)-1,2bis[(2R,5R)-2,5-dimethylphospholan] benzene, (2R,2'R,5R,5'R)2,2',5,5'-tetramethyl-1,1'-(o-phenylene)diphospholane(MeDufos), xyliphos, josiphos, enantiomers or similar enzymes / mers. Petition 870250088165, of 29 / 09 / 2025, p. 44 / 82 26 / 46
[0086] The term bidentate chiral ligand containing nitrogen, as used in this document in some embodiments, may refer to a bidentate chiral ligand containing one or more nitrogen atoms, which is linked to the rest of the molecule by a single or double bond, and the rest of the molecule may be an organic or organometallic molecule. For example, and not limited to, (3aR,3'aR,8aS,8'aS)-3a,3'a,8a,8'a-tetrahydro-8H,8'H-2,2'biindene[1,2-d]oxazole, (5R,5'R)-5,5'-diisobutyl-4,4',5,5'tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-diphenyl-4,4',5,5'tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-dibenzyl4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-di-tert-butyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-dimethyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-diisopropyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, derivatives or enantiomers thereof and / or similar substances.
[0087] The term transition metal, as used in this document in some embodiment, may refer to a metal selected from the transition metal group of the Periodic Table with an oxidation state of -4, -3, -2, -1, 0, +1, +2, +3, +4, +5, +6 or +7.
[0088] The term cationic transition metal, as used in this document and in some embodiments, may refer to a positively charged metal selected from the transition metal group of the Periodic Table with an oxidation state of +1, +2, +3, +4, +5, +6, or +7. Non-limiting examples of cationic transition metals are: Cu+, Ni+, Fe+, Ru+, Cr+, Mo+, W+, Co+, Mn+, Cu2+, Ni2+, Pd2+, Pt2+, Fe2+, Ru2+, Cr2+, Mo2+, W2+, Co2+, Mn2+, Cu3+, Ni3+, Pd3+, Fe3+, Petition 870250088165, dated 09 / 29 / 2025, p. 45 / 82 27 / 46 Ru3+, Cr3+, Mo3+, W3+, Co3+, Mn3+, Ni4+, Pt4+, Fe4+, Ru4+, Cr4+, Mo4+, W4+, Mn4+ and / or similar.
[0089] According to some embodiments, the process may use a catalyst. According to some embodiments, the catalyst may be a complex of a transition metal with a chiral monodentate, bidentate, or polydentate ligand. According to some embodiments, the transition metal may be a cationic transition metal. According to some embodiments, the complex may be prepared in situ or ex situ.
[0090] All abbreviations, including chemical abbreviations, have commonly accepted meanings.
[0091] For the purposes of better understanding the present teachings and in no way limiting the scope of the teachings, unless otherwise indicated, all numbers expressing quantities, percentages or proportions and other numerical values used in the descriptive report and claims should be understood as being modified in all cases by the term "approximately". Accordingly, unless otherwise indicated, the numerical parameters presented in the following descriptive report and appended claims are approximations that may vary depending on the desired properties to be obtained. At a minimum, each numerical parameter should be interpreted in light of the number of significant digits reported and by applying customary rounding techniques. In this respect, the term "approximately" used in this document specifically includes ±10% of the values indicated in the range.Additionally, the endpoints of all ranges directed to the same component or... Petition 870250088165, dated 09 / 29 / 2025, page 46 / 82 28 / 46 properties here include endpoints, are independently combinable, and include all intermediate points and ranges. Similarly, the ranges and quantities for each element of the technology described here can be used in conjunction with ranges or quantities for any of the other elements.
[0092] Any desired range or value provided in this document may be extended or altered without losing the intended effects, which is evident to the expert in the technique for understanding the teachings contained herein.
[0093] The following examples are included for illustrative purposes only and should not be construed as limitations of the invention claimed herein. EXAMPLES Example 1: Synthesis of 2,6-dimethyl-2,3-dihydro-1H-inden-lol (III) o OH \ NaBH4 / Ethanol CAS # 15153 09- 83-9 CAS # 8 8ÜÓ 5 3 -Ó9-Ü
[0094] To a solution of 2,6-dimethyl-1-indanone (50 g) in ethanol (500 ml), NaBH4 (14.3 g) was added in portions at 10 °C. The reaction was heated to 25 °C and stirred for a further 4 h. The consumption of the starting material was monitored by TLC. Once the starting material was consumed, water (100 ml) was added until solids formed. The ethanol was evaporated under vacuum. 160 ml of water was added and 32% HCl was added to neutralize the reaction medium to pH = 7. The extraction was performed twice with 150 ml of Petition 870250088165, dated 09 / 29 / 2025, page 47 / 82 29 / 46 ethyl acetate, followed by phase separation. Ethyl acetate was removed from the organic phase, resulting in a yield of 50.6 g of pure 2,6-dimethyl-2,3-dihydro-1H-indenl-ol. Example 2: Synthesis of the 2,5-dimethylindene compound of Formula (II) pTSA Cat. toluene 2,5-dimethylindene
[0095] A catalytic amount of p-toluenesulfonic acid (pTSA) was added to a solution of 2,6-dimethyl-2,3-dihydro-1-indan-1-ol (50 g) in toluene (250 ml) at 25 °C. The solution was heated to 90 °C and stirred until all the starting material was consumed. The reaction was cooled to 25 °C and washed twice with 150 ml of water. After phase separation, the toluene was evaporated to yield 45 g of 2,5-dimethylindene, with a purity > 90%. The 2,5-dimethylindene was further purified by column chromatography or by crystallization in methanol. Petition 870250088165, dated 09 / 29 / 2025, pp. 48 / 82 30 / 46 Example 3: Synthesis of (1.R, 2S)-1-amino-2,6-dimethylindan 2,5-dimethylindene mmol l)Cu(OAc),(1 mol%) (SS)-Ph-BPE (1.1 mol%) NH. Al (5 equiv.) PMHS 15 equiv.) cyclohexane (0.3 M). 70°C „ * I (lR,2S)-l-annino-2,6-dimethylindan 2) NH3OH'HCl in methanol (SS)-Ph-BPE CAS # 824395-67-7 Al l .Z-benzisoxazole. CAS #271-95-4
[0096] An oven-dried flask was loaded with copper(II) acetate (Cu(OAc)2) (5.4 mg, 1 mol%) and (+)-1,2bis((2S,5S)-2,5-diphenylphospholane)ethane ((S,S)-Ph-BPE) (16.7 mg, 1.1 mol%) under a nitrogen atmosphere. Cyclohexane (10 mL) and poly(methylhydrosiloxane) (PMHS) (5 equivalents) were added sequentially with a syringe, and the reaction mixture was stirred at room temperature (about 25 °C) for 30 min. Then, 2,5-dimethylindene (432 mg, 3 mmol, 1.0 equivalent) was added to the solution. A solution of Al (1,2-benzisoxazole) (15.0 mmol, 5.0 equivalents) in cyclohexane was added dropwise over a period of 16 h to produce an imine of Formula (IX) Petition 870250088165, dated 09 / 29 / 2025, page 49 / 82 31 / 46 (IX).
[0097] Dichloromethane (10 mL) and a methanolic solution of NH2OH*HCl (0.5 M, 10 mL) was added to the crude reaction mixture over a period of 2 hours to hydrolyze the imine and obtain the amine hydrochloride salt. The crude reaction mixture was then concentrated under reduced pressure, the residue was neutralized with 2.5 M NaOH solution (15 mL), tetrahydrofuran (15 mL) was added, and the mixture was stirred for 24 hours to produce the free amine (1R,2S)-1amino-2,6-dimethylindane. The aqueous layer was then extracted with EtOAc (20 mL, 5 times). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated under reduced pressure.
[0098] (1R,2S)-1-amino-2,6-dimethylindane was isolated by column chromatography, with a yield of 74% and an enantiomeric excess (ee) of 98%. Example 4: Screening of amine sources
[0099] Several amines were screened for use in the synthesis of (1R,2S)-1-amino-2,6-dimethylindane. Table 1 presents a list of exemplary amines tested under various reaction conditions. Petition 870250088165, dated 09 / 29 / 2025, pp. 50 / 82 Table 1 Example 5: Screening of silane sources 0.5 mmol 1) Cu(OAc)2(5 inol%) (S,S)-Ph-BPE (5.5 mol%) NH, Al (3 equiv., added slowly over 12h) Silane (5 equiv.) (1R, 2S)-1-amino-2,6-dimethylindan Cyclohexane (0.2 M), 70°C 2) CH₂OH·HO in methanol
[0100] Several silanes were screened for use in the synthesis of (IR, 2S)-1-amino-2,6-dimethylindane, wherein Al is 1,2-benzisoxazole, as defined in Example 3. Table 2 presents a list of exemplary silanes tested under various reaction conditions. Petition 870250088165, dated 09 / 29 / 2025, pp. 51 / 82 33 / 46 Table 2 Silane Result oo Z^ ^SiH^ Methyldimethoxysilane (DMMS) 58% isolated yield 'Ύ . _ DMMS + t-butaniol (2.5 equivalents) 33% isolated yield \ Ο γ) / Poly(methylhydrosilane) (PMHS) 40% NMR yield 36% isolated yield Example 6: Screening of solvents for copper catalysts 2,5-dimethylindene 0.5 mmol 1) Cu(OAc), (5 niol%) (S,S)-Ph-BPE (5.5 iuol%) NH2 Al (3 equiv., added slowly over 12h) PMHS (5 equivalents) (1R,2S)-1-amino-2,6-dimethylindan Solvent (0.2 M), 70°C 2) NH,OH*HC1 in methanol
[0101] Several solvents or solvent mixtures were screened for use in the synthesis of (IR,2S)-1-amino2,6-dimethylindane, wherein Al is 1,2-benzisoxazole, as in Example 3. Table 3 presents a list of exemplary solvent systems tested under various reaction conditions. Petition 870250088165, dated 09 / 29 / 2025, pp. 52 / 82 34 / 46 Table 3 Solvent Systems Results (% conversion or yield) Toluene 54% yield Methylcyclohexane 85% conversion n-heptane 61% conversion Example 7: Nickel-catalyzed asymmetric hydroalkylamination 2,5-dimethylindene 0.5 mmol NBn, Ni(OAc)2(5 mol%) OBz L5 (6 mol%)+I -----------------(OMe)3SiH (2.5Bn B11Nal(15mol%) O-benzoil-N,N-dibenzil- THF (0,5 M). ta, 48h hidroxilamina (ll?,2S)-1-dibenzillamino-2,6-dimetilindano 0,75 imnol (SR.S'RJ-S.S'-di-ferc-butil^q'.S.S'-tetra-hidro^p'-bioxazol
[0102] In an argon-filled glove box, NIOAC2 (4.4 mg, 0.025 mmol, 5.0 mol%), L5 binder ((5R,5'R)~ 5,5'-di-tert-butyl-4,4',5,5'-tetrahydro-2,2'-bioxazole (9.5 mg, 0.030 mmol, 6.0 mol%), sodium iodide (NaI) (11.2 mg, 0.075 mmol, 15 mol%), anhydrous tetrahydrofuran (THE) (1.0 mL, 0.5 M) were added to a 10 mL screw-capped flask fitted with a magnetic stir bar, and the mixture was stirred for 30 min; then, trimethoxysilane ((MeO)3SIH) (160 µL, 1.25 mmol, 2.5 equivalents), 2,5-dimethylindene (72 mg, 0.50 mmol) and benzoyl-N,N-dibenzylhydroxylamine (Bn2NOBz) (238 mg, 0.75 mmol, 1.5 equivalents) were added sequentially. The reaction was stirred at room temperature for 48 h. After the reaction was complete, it was stopped by adding water. Petition 870250088165, dated 09 / 29 / 2025, pp. 53 / 82 35 / 46 and the mixture was extracted with dichloromethane (three times). The organic layer was concentrated. The crude material was purified by flash column chromatography (petroleum ether / ethyl acetate = 200:1 to 50:1) to provide (IR,2S)-1-dibenzylamino-2,6-dimethylindane as a colorless oil. Without being bound to any theory, the iodide ion (from NaI) may generate nickel diiodide in situ, which may be more reactive than Ni(OAc)2. This may aid in the formation of the nickel-bidentate ligand complex, which was obtained with 60% conversion and 91.5% enantiomeric excess (ee). Example 8: Nickel-catalyzed asymmetric hydroalkylamination 2,5-dimethylindene 0.5 mmol OBz I N Bti^ ^Bii Ni(OAc)2(5 mol%) LI (6 mol%) NBn2(OMe)3SiH(2.5 equiv.) NaI (15 mol%) THF (0.5 M). ok, 48h (lfi,2S)-1-dibenzylamino-2,6-dimethylindan O-benzoyl-N,N-dibenzylhydroxylamine 0.75 tninol CAS# 1354558-61-4
[0103] In an argon-filled glove box, NIOAC2 (4.4 mg, 0.025 mmol, 5.0 mol%), L1 ligand (3'aR,3aR,8'aS,8aS)-3'a,3a,8'a,8a-tetrahydro-2,2'-bi-8Hindeno[1,2-d]oxazole (9.5 mg, 0.030 mmol, 6.0 mol%), sodium iodide (NaI) (11.2 mg, 0.075 mmol, 15 mol%), anhydrous tetrahydrofuran (THF) (1.0 mL, 0.5 M) were added to a 10 mL screw-capped flask fitted with a magnetic stir bar, and the mixture was stirred for 30 min; then trimethoxysilane ((MeO)3SiH) (160 pL, 1.25 Petition 870250088165, dated 09 / 29 / 2025, pp. 54 / 82 36 / 46 mmol, 2.5 equivalents), 2,5-dimethylindene (72 mg, 0.50 mmol) and O-benzoyl-N,N-dibenzylhydroxylamine (Bn2NOBz) (238 mg, 0.75 mmol, 1.5 equivalents) were added sequentially. The reaction was stirred at room temperature for 48 h. After the reaction was complete, it was quenched by adding water and the mixture was extracted with dichloromethane (three times). The organic layer was concentrated. The crude material was purified by flash column chromatography (petroleum ether / ethyl acetate = 200:1 to 50:1) to give (IR,2S)-1-dibenzylamino-2,6-dimethylindane as a colorless oil. Without being tied to any particular theory, the iodide ion (from NaI) can generate nickel diiodide in situ, which may be more reactive than Ni(OAc)2. This could aid in the formation of the bidentate nickel ligand complex, which was obtained with a 40% yield and 95% enantiomeric excess. Example 9: Nickel-catalyzed asymmetric hydroalkylamination 2,5-dimethylindene inmol O-benzoyl-N,N-dibenzylhydroxylamine 1.2 mmol Nil2(1 mol%) LI (1.1 mol%) NBn, ÍOMeipiH (1.5 equiv.) NaI (1 mol%) THF (2 M). rt(10-20°C), 96 h (1S,25^-1-dibenzylamino-2,6-dimethylindane
[0104] In a glove box filled with argon, NiI2 (1.0 mol%), L1 ligand as defined in Example 8 (1.1 mol%), sodium iodide (1 mol%), anhydrous tetrahydrofuran (2 M) were added to a 10 mL screw-top flask fitted with a magnetic stirring bar, and the Petition 870250088165, dated 09 / 29 / 2025, pp. 55 / 82 The 37 / 46 mixture was stirred for 30 min; then, trimethoxysilane (1.5 equivalents), 2,5-dimethylindene (1 mmol), and O-acetyl-N,N-dibenzylhydroxylamine (Bn2NOAc) (1.2 mmol) were added sequentially. The reaction was stirred at room temperature for 96 h. After the reaction was complete, it was quenched by adding water, and the mixture was extracted with dichloromethane (three times). The organic layer was concentrated. The crude material was purified by flash column chromatography (petroleum ether / ethyl acetate = 200:1 to 50:1) to provide (1R,2S)-1-dibenzylamino-2,6-dimethylindane as a colorless oil with 78% conversion, 74% NMR yield, and 96.7% enantiomeric excess (ee). Example 10: Reduction of (IR,2S)-N,N-dibenzyl-2,6-dimethyl-2,3-dihydro-1H-inden-1-amine to (1R,2S)-2,6-dimethyl-2,3-dihydro-1H-inden-1-amine Pd catalyst (1R,2S)-N,N-dibenzyl-2,6-dimethyl-2,3- (1R,2S)-2,6-dimethyl-2,3-dihydro-1 Hd ihydro-1 H-inden-1 -amine inden-1 -amine
[0105] In a flask containing (IR,2S)-N,N-dibenzyl-2,6-dimethyl-2,3-dihydro-1H-inden-1-amine (341 mg, 1 mmol), Pd / C (10% by weight of Pd, 100 mg) and methanol (100 ml). The hydrogen was purged with a flask (1 atm) and the mixture was stirred at room temperature for 12 h. The reaction mixture was filtered through a Celite pad, and the filtrate was concentrated under reduced pressure to give (IR,25)-2,6Petition 870250088165, dated 29 / 09 / 2025, page 56 / 82 38 / 46 dimethyl-2,3-dihydro-1H-inden-1-amine (160 mg, >99% yield). Example 11: Screening of nickel catalysts for benzoyl amination reagent
[0106] Several nickel-containing catalysts were screened for use in the synthesis of (1R,2S)-1-dibenzylamino-2,6-dimethylindane, wherein the L1 ligand is as defined in Example 8. Table 4 presents a list of exemplary nickel-containing catalysts tested under various reaction conditions. 2,5-dimethylindene O-benzoyl-N,N-dibenzylhydroxylamine Ni-Cat. (5 mol%) LI (7 mol%) NBn, (OMe)3SiH-(2.5 equiv.) NaI (15 mol%) THF, 30“C 48 h (lR,2Spi-dibenzylamino-2,6-dimethylindane Table 4 Nickel Catalyst ee (%) Ni (BF4) 2· 6H2O Nickel(II) tetrafluoroborate hexahydrate 92 NiF2*4H2O Nickel difluoride tetrahydrate 91 Ni(AcAc)2 Nickel(II) bis(acetylacetonate) 93 N1I2 Nickel iodide 93 Ni(CF3CO2)2 Nickel(II) trifluoroacetate 92 Petition 870250088165, dated 09 / 29 / 2025, pp. 57 / 82 39 / 46 Example 12: Screening of nickel catalyst for acetoxy amination reagent
[0107] Several nickel-containing catalysts were screened for use in the synthesis of (1R,2S)-1-dibenzylamino-2,6-dimethylindane, wherein the LI ligand is as defined in Example 8. Table 5 presents a list of exemplary nickel-containing catalysts tested under various reaction conditions. 2,5-dimethylindene O-acetyl-N,N-dibenzylhydroxylamine mmol 1.2 mmol NBi^ Ni-Cat. (1 inol%) LI (1.1 mol%) (OMe)3SÍH (1.5 equiv.) Nai (1 inol%) THF (2 M), 30°C 96 h (1S.2S)-1-dibenzylamino-2,6-dimethylindan Table 5 Nickel catalyst ee (%) Ni(OAc)2 Nickel(II) acetate 95 Ni(OSO2CF3)2 Nickel(II) trifluoromethanesulfonate 97 NiI2 nickel iodide 96.7 Ni(ClO4)2·6H2O Nickel(II) perchlorate hexahydrate 97 Ni(BF4)2·6H2O Nickel(II) tetrafluoroborate hexahydrate 96.4 Ni(NTf2)2 Nickel bis(trifluoromethylsulfonyl)imide 93 Petition 870250088165, dated 09 / 29 / 2025, pp. 58 / 82 40 / 46 Nickel catalyst ee (%) Ni(AcAc)2 Nickel(II) bis(acetylacetonate) 96 NiBr2*DME Nickel bromide dimethyl ether 96.5 NiBr2*6H2O Nickel bromide hexahydrate 84 N1CI2 Nickel chloride 96.4 NiC12*6H2O Nickel chloride hexahydrate 96.4 NiC12*DME Nickel chloride dimethyl ether 94 Example 13: Screening of solvents for use with a benzoyl amination reagent with a nickel catalyst.
[0108] Various solvents or solvent mixtures were screened for use in the synthesis of (IR,2S)-1-dibenzylamino-2,6-dimethylindane, wherein Liquant 1 is as defined in Example 8. Table 6 presents a list of exemplary solvent systems tested under various reaction conditions. NBu, Ni(BF4)26H2O (5 n»l%) LI (7 mol%) (OMe)3SiH (2.5 equiv.) NaI (15 mol%) 2,5-dimethylindene O-benzoyl-N,N-dibenzyl- Solvent, 30°C. 48 h hydroxylamine (1A,2S)-1-dibenzylamino-2,6-dimethylindan Table 6 Solvent ee (%) Dichloromethane 88 Dichloromethane (5°C) 93 Acetonitrile 91 Petition 870250088165, dated 09 / 29 / 2025, pp. 59 / 82 41 / 46 Solvent ee (%) 1,4-dioxane (60°C) 87 Acetonitrile 77 Acetonitrile (60°C) 66 Dimethylacetamide 67 Example 14: Screening of solvents for use with a nickel catalyst with acetoxy amination reagent. 2,5-dimethylindene mmol OAc+I N BtM on O-acetyl-N,N-dibenzylhydroxylamine NBn, NH2(1 mol%) LI (1.1 mol%) (OMe)}SiH(1.5 Nai (1 mol%) Solvent (2 M), ta (10-20“C), 96 h (1A,2S)-1-dibenzylamino-2,6-dimethylindan 1.2 mmol
[0109] Several nickel-containing catalysts were screened for use in the synthesis of (1R,2S)-1-dibenzylamino-2,6-dimethylindane, wherein the LI ligand is as defined in Example 8. Table 7 presents a list of exemplary solvent systems tested under various reaction conditions. Table 7 Solvent ee (%) Tetrahydrofuran 97 Dichloromethane 96 Diethyl ether 96 1,4-dioxane 96 Dimethylacetamide 96 Cyclopentyl methyl ether 95 Petition 870250088165, dated 09 / 29 / 2025, pp. 60 / 82 42 / 46 Example 15: Screening of chiral nitrogen ligands
[0110] Several bidentate chiral ligands containing nitrogen were screened for use in the synthesis of (IR,2S)-1-dibenzylamino-2,6-dimethylindane. Table 8 presents a list of exemplary solvent systems tested under various reaction conditions. Ni(OAc),(5 mol%) 2,5-dimethylindene 0.5 mmol OBz N Bn-^ ^-Bn O-benzoyl-N,N-dibenzylhydroxylamine 0.75 mmol NBn, Binder (6 inol) (OMe)3SiH (2.5 equiv.) NaI (15 mol%) THF (0.2 M), rt, 48h (17.25)-1-dibenzylamino-2,6-dimethylindan Table 8 Ligand Results (f=\ ..... / \ (3aR, 3 ' aR, 8aS, 8 ' aS) - 3a,3'a,8a,8'a-tetrahydro- 8H,8'H-2,2'-biindeno[1,2— d]oxazole 92% conversion, ee of 92.6% CK AχA (5R,5'R)-5,5'-diisobutyl- 4,4',5,5'-tetrahydro-2,2'bioxazole 77% conversion, ee of 59% 1 oo 84% conversion, ee of 81% Petition 870250088165, dated 09 / 29 / 2025, pp. 61 / 82 43 / 46 Ligand Results (5B,5'B)-5,5'-diphenyl-4,4',5,5'-tetrahydro-2,2'-bioxazole L J. u N^X Bn Bn (5R,5'R)-5,5'-dibenzyl-4,4',5,5'-tetrahydro-2,2'-bioxazole 62% conversion, ee of 73% (5B,5'B)-5,5'-di-tert-butyl-4,4',5,5'-tetrahydro-2,2'-bioxazole 60% conversion, ee of 91% O. LA ν' n br x (5R,5'R)-5,5'-dimethyl-4,4',5,5'-tetrahydro-2,2'-bioxazole 76% conversion, ee of 55% (5R,5'R)-5,5'-diisopropyl-4,4',5,5'-tetrahydro-2,2'-bioxazole 60% conversion, ee 65% Example 16: Synthesis of (1R,2S)-1-dibenzylamino-2,6-dimethylindane using a nickel catalyst with and without sodium additive.
[0111] The synthesis of (IR,2S)-1-dibenzylamino-2,6-dimethylindane using a nickel catalyst from Example 7 was tested with (A) and without (B) an additive of sodium iodide. Petition 870250088165, dated 09 / 29 / 2025, pages 62 / 82 44 / 46 0.5 mmol of indene and 0.75 mmol of benzoyl amination reagent were used under identical reaction conditions, with L1 as defined in Example 8. Higher conversion and enantiomeric excess were obtained with the addition of a sodium additive. 2,5-dimethylindene 0.5 mmol O-benzoyl-N,N-dibenzyl-THF (0.5 M), 5-10 °C, 48 hee:94 go^ hydroxylamine 0.75 mmol (U?,2S)-1-dibenzylamino-2,6-dimethylindan NBn, 2,5-dimethylindene 0.5 mmol Ni(OAc) (5 mol%) Bn^ Bn Nal(0mol%) λ / ί. THF (0.5 M), 5-10 °C, 48 h !8%Conv. O-benzoyl-N,N-dibenzylhydroxylamine (U?,2S^-1-dibenzylamino-2,6-dimethylindan 0.75 mmol Example 17: Additive screening
[0112] Several iodide additives were screened for use in the synthesis of (IR,2S)-1-dibenzylamino-2,6-dimethylindane using a nickel catalyst reaction similar to that of Example 8, with LI as defined in Example 8. Table 9 presents a list of exemplary solvent systems tested under the same reaction conditions. Petition 870250088165, dated 09 / 29 / 2025, pp. 63 / 82 45 / 46 Table 9 Additive (x % in mol Conversion) KI (15 % in mol) 40% LII (15 % in mol) 26% CSI (15 % in mol) 35% Nai (15 % in mol) 57% Nai (10 % in mol) 58% Nai (5 % in mol) 77% Nai (2.5 % in mol) 90% Example 18: Screening of amine reagents for nickel catalyst
[0113] Several amine reagents were screened for use in the synthesis of (1R,2S)-1-dibenzylamino-2,6-dimethylindane using a nickel catalyst reaction similar to that of Examples 8 and 9. Table 10 is a list of exemplary amination reagents tested under the same reaction conditions. 2,5-dimethylindene 0.5 mmol THE I N Bit Bn 0.75 mmol Ni(OAc)2 (5 mol%) Ll (6mol%) NBil (OMe)3SiH (2.5 eqniv) Nai (15 inol%) THF (0.5 M), ia (20-30°C), 48 li (1S,2S)-1-dibenzylamino-2,6-dimethylindan Petition 870250088165, dated 09 / 29 / 2025, pp. 64 / 82 46 / 46 Table 10 Reagent for animation Results CO2Et N Bn^ ^Bn 85% conversion OBz N Bn^ ^Bn O-benzoyl-N,N-dibenzylhydroxylamine 93% conversion, ee of 92.6% OAc N Bn^ ^Bn O-acetyl-N,N-dibenzylhydroxylamine 90% conversion, ee of 92.7%
[0114] Although several exemplary aspects and embodiments have been discussed above, those skilled in the art will recognize certain modifications, additions, and subcombinations thereof. It is therefore intended that the following appended claims and claims set forth below be interpreted to include all modifications, additions, and subcombinations that are within their true spirit and scope. Petition 870250088165, dated 09 / 29 / 2025, pp. 65 / 82
Claims
1 / 11 1. Process for CLAIMS the preparation of an amine compound of Formula (I): characterized in that: R1 and R2 are each independently hydrogen or an optionally substituted C1-C4 alkyl group, and wherein R1 and R2 are not both hydrogen; R3 and R4 are each independently hydrogen, an optionally substituted C1-C3 alkyl group, an optionally substituted C1-C3 alkenyl group, an optionally substituted aryl group, a phenyl or aralkyl group with a C1-C4 alkyl chain; wherein the optional substituent is selected from the group comprising halogen, aliphatic, halo aliphatic, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; A is -CH2-, -O- or a direct linkage; en is 0, 1, 2 or 3;comprising the amination of an indene compound of Formula (II) ^R1(R)n—xJLa —Formula (II) with an aminating agent selected from a compound of Formula (IV) or Formula (VI), Petition 870260107969, 21 / 10 / 2026, p. 9 / 38 2 / 11 R5 ''''' / °\ 'Ά n Formula (IV) Formula (VI) where : R5 is COOR6, OR7 or OC=OR8; R6, R7 and R8 are each independently hydrogen, an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from among one or more group substituents comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro;R9 and R10 are each independently an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; A' is -CH2- or a direct linkage; and A'' is a fused benzene ring optionally substituted by (R2)n, wherein n and R2 are as defined in Formula (I); wherein the amination occurs in the presence of a hydrosilane reducing agent and a catalyst, wherein the catalyst is a complex of a transition metal with a chiral monodentate, bidentate or polydentate ligand. Petition 870260107969, 10 / 21 / 2026, p. 10 / 38 3 / 11; 2. Process according to claim 1, characterized in that: a) R1 and R2 are each independently C1-C4 alkyl groups; and / or b) R3 and R4 are each independently hydrogen.
3. Process according to claim 1 or 2, characterized in that the compound of Formula (I) is: a) (1R,2S)-1-amino-2,6-dimethylindane (Formula VII); or b) (1R,2S)-1-dibenzylamino-2,6-dimethylindane.
4. Process, according to any one of claims 1 to 3, characterized in that: a) the hydrosilane reducing agent is selected from the group comprising alkoxy-hydrosilanes or hydrosiloxanes; b) the transition metal has an oxidation state of 0, +1, +2, +3 or +4; c) the complex of a transition metal with a chiral ligand is prepared in situ; d) the chiral ligand is a bidentate chiral ligand; e) the amination is carried out in a solvent; and / or f) the amination occurs at a temperature in the range of approximately 0 to 100°C.
5. Process according to claim 4, characterized in that: a) the hydrosilane reducing agent is selected from the group comprising methyldimethoxysilane, trimethoxysilane or poly(methyl-hydrosiloxane); b) the transition metal has an oxidation state of +2; and / or Petition 870260107969, dated 10 / 21 / 2026, page 11 / 38 4 / 11 c) the transition metal is selected from the group comprising Cu2+, Ni2+, Pd2+, Pt2+, Fe2+, Ru2+, Cr2+, Mo2+, W2+, Co2+ and Mn2+.
6. Process, according to any one of claims 1 to 5, characterized in that the chiral ligand is a bidentate chiral ligand containing phosphorus.
7. Process according to claim 6, characterized in that the bidentate chiral ligand containing phosphorus is selected from the group consisting of: (+)-1,2-bis((2S,5S)-2,5-diphenylphospholane)ethane, (+)-1,2-bis((2S,5S)-2,5-dipropylphospholane)ethane, (-)-1,2-bis[(2R,5R)-2,5-diethylphospholane]benzene, (-)-1,2-bis[(2R,5R)-2,5-dimethylphospholane]benzene, 1,2-bis(diphenylphosphino)ethane (DPPE), (+)-2,2-dimethyl-4,5-((diphenylphosphino)dimethyl)dioxolane, (2S,4S)-(-)-4-diphenylphosphino-2-(diphenylphosphinomethyl)pyrrolidine, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl) (BINAP), (-)-1,2-bis[(2R,5R)-2,5-dimethylphospholano]benzene, derivatives and enantiomers thereof.
8. Process according to claim 6 or 7, characterized in that the aminating agent is a compound of Formula (IV) wherein: R5 is COOR6, OR7 or OC=OR8; R6, R7 and R8 are each independently hydrogen, an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of Petition 870260107969, of 10 / 21 / 2026, p.12 / 38 5 / 11 group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic halo group, alkoxy halo group, thioalkyl halo group, hydroxyl halo group, cyano halo group, aryl halo group, and nitro halo group; R9 and R10 are each independently an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic halo group, alkoxy halo group, thioalkyl halo group, hydroxyl halo group, cyano halo group, aryl halo group, and nitro halo group; or a compound of Formula (VI) wherein: A' is -CH2-; A'' is a fused benzene ring optionally substituted with (R2)n, wherein n and R2 are as defined in Formula (I); n is 0.
9. Process according to claim 8, characterized in that the aminating agent is 1,2-benzisoxazole.
10. Process, according to any one of claims 6 to 9, characterized in that: a) the solvent is selected from a group consisting of: tetrahydrofuran, 2-methyltetrahydrofuran, cyclohexane, methylcyclohexane, toluene, n-heptane, methyl tert-butyl ether, cyclopentylmethyl ether, chlorobenzene, diethyl ether, dichloroethane, dichloromethane and xylene; Petition 870260107969, dated 10 / 21 / 2026, page 13 / 38 6 / 11 b) the hydrosilane reducing agent is selected from methyldimethoxysilane and poly(methylhydrosiloxane); and / or c) the transition metal is Cu2+, selected from copper(II) acetate, copper(II) nitrate, copper(II) carbonate, copper(II) sulfate, copper(II) trifluoroacetate, copper(II) triflate, copper(II) bis(trifluoromethylsulfonyl)imide, copper(II) perchlorate, copper(II) tetrafluoroborate hexahydrate.
11. A process according to any one of claims 6 to 10, characterized by further comprising the addition of a hydrolyzing agent to hydrolyze an initially formed imine derivative to obtain a free amine or a salt thereof, wherein the hydrolyzing agent is selected from among: NH2OH-HCl, NH3 (ammonia), N2H4 (hydrazine), and NH2OH 50% by weight in H2O.
12. Process, according to any one of claims 1 to 5, characterized in that the chiral ligand is a bidentate chiral ligand containing nitrogen.
13. Process according to claim 12, characterized in that the nitrogen-containing bidentate chiral ligand is selected from the group consisting of: (3aR,3'aR,8aS,8'aS)-3a,3'a,8a,8'a-tetrahydro-8H,8'H-2,2'-biindeno[1,2-d]oxazole, (5R,5'R)-5,5'-diisobutyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-diphenyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-dibenzyl Petition 870260107969, of 10 / 21 / 2026, p. 14 / 38 7 / 11 4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-di-tert-butyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-dimethyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, (5R,5'R)-5,5'-diisopropyl-4,4',5,5'-tetrahydro-2,2'-bioxazole, derivatives and enantiomers thereof.
14. Process according to claim 12 or 13, characterized in that the aminating agent is a compound of Formula (IV) wherein: R5 is COOR6, OR7 or OC=OR8; R6, R7 and R8 are each independently hydrogen, an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro; R9 and R10 are each independently an optionally substituted C1-C4 alkyl chain or an optionally substituted aryl group, wherein the optional substituent is selected from one or more substituents of the group comprising halogen, C1-C4 alkyl chain, aliphatic halo group, alicyclic, alkoxy, thioalkyl, hydroxyl, cyano, aryl and nitro.
15. Process, according to any one of claims 12 to 14, characterized in that: Petition 870260107969, dated 10 / 21 / 2026, page 15 / 38 8 / 11 a) the aminating agent is selected from (Bn)2NOBz (O-benzoyl-N,N-dibenzylhydroxylamine), (Bn)2NOAc (O-acetyl-N,N-dibenzylhydroxylamine) and (Bn)2NCO2Et; b) the solvent is selected from tetrahydrofuran, 1,2-dichloroethane, 1,4-dioxane, acetonitrile, dimethylacetamide, dichloromethane, cyclopentylmethyl ether, dimethoxymethane, methyl tert-butyl ether, chlorobenzene, diethyl ether, 2-methyl tetrahydrofuran and dichloromethane; c) the hydrosilane reducing agent is trimethoxysilane; and / or d) the transition metal is Ni2+, selected from nickel diiodide, nickel(II) tetrafluoroborate hexahydrate, nickel(II) bis(acetylacetonate), nickel dichloride, nickel difluoride tetrahydrate and nickel(II) trifluoroacetate.
16. Process, according to any one of claims 12 to 15, characterized by further comprising the addition of an additive selected from the group consisting of sodium iodide (NaI), potassium iodide (KI), lithium iodide (LI) and cesium iodide (CSI).
17. Process according to claim 3, characterized in that (IA,2S)-1-amino-2,6-dimethylindane (Formula (VII)) nh2 F ó r mu 1 a (VII) is produced by the reaction of 2,5-dimethylindene having a Formula (VIII) Petition 870260107969, of 10 / 21 / 2026, p. 16 / 38 9 / 11 Formula (VIII) with 1,2-benzisoxazole in the presence of copper(II) acetate (Cu(OAc)2), (+)-1,2-bis(2S,5S)-2,5-diphenylphospholane)ethane ((S,S)-Ph-BPE) and poly(methylhydrosiloxane) (PMHS) and the addition of NH2OH-HCl to produce (IF,2S)-1-amino-2,6-dimethylindane (Formula (VII)).
18. Process according to claim 17, characterized in that: a) the process takes place under a nitrogen atmosphere; and / or b) the amination is carried out in a solvent, wherein the solvent is selected from a group consisting of: tetrahydrofuran, 2-methyl-tetrahydrofuran, methylcyclohexane, toluene, n-heptane, methyl tert-butyl ether, cyclopentylmethyl ether, chlorobenzene, diethyl ether, dichloroethane, dichloromethane, xylene and 1,4-dioxane.
19. 2,5-dimethylindane compound, characterized by being a compound of Formula (VIII):
20. Compound, characterized by the fact that it is a compound of Formula (IX): Petition 870260107969, of 10 / 21 / 2026, page 17 / 38 10 / 11 (IX).
21. Process, according to any one of claims 1 to 18, characterized in that the compound of Formula (IX) is an intermediate in the preparation of a compound of Formula (I).
22. Process for the preparation of Indaziflam, characterized in that it comprises the preparation of a compound of Formula (I) according to the process of any one of claims 1 to 18, wherein A is a direct linkage, R1 and R2 are alkyl C1en = 1.
23. Process for the preparation of Indaziflam, characterized in that the process comprises: a. reacting (1R,2S)-1-amino-2,6-dimethylindane prepared according to any one of claims 1 to 18 with 1-cyanoguanidine in the presence of a solvent to obtain (1R,2S)-1-(bisguanidino)-2,6-dimethylindane; and b. reacting said (1R,2S)-1-(bisguanidino)-2,6-dimethylindane with methyl-(2R)-2-fluoropropanoate in the presence of a base and in the presence of a solvent.
24. Process for the preparation of Indaziflam, characterized in that the process comprises: a. reacting (1R,2S)-1-amino-2,6-dimethylindane prepared according to any one of claims 1 to 18 with 1-cyanoguanidine and metal isopropoxide in the presence of a solvent to obtain (1R,2S)-1-(bisguanidino)-2,6-dimethylindane; and b. reacting said (1R,2S)-1-(bisguanidino)-2,6-dimethylindane with methyl-(2R)-2-fluoropropanoate.
